|
Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacy
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
Zahlen und Fakten zur Studie: | 273+44 seiten | |||||||||
| Inhalt der Studie: |
Introduction
At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaici.....
Introduction At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU; and the high-profile failure of ralfinamide (NW-1029; Newron) for the treatment of neuropathic low back pain. Features and benefits * Analysis of patient segmentation, epidemiology, current treatment approaches, and clinical unmet needs.* In depth analysis of historic (2005–09) and future (2010–19) seven major market prescription sales dynamics.* Discussion of R&D dynamics and pipeline trends in the neuropathic pain market.* Commercial and clinical assessment of key late-stage pipeline drugs with country-specific sales forecasts to 2019.* Insight provided by eight international key opinion leaders. Highlights The neuropathic pain market is expected to achieve peak sales of $4.1bn over the forecast period (2010–19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to enter the neuropathic pain market over the forecast period (2010–19) across the seven major markets.The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Grünenthal) will drive market growth, while the launch of novel and topical agents will broaden treatment options. Your key questions answered * Who will be the winners and losers in the future neuropathic pain market?* What are the key unmet needs in the treatment of neuropathic pain?* What are the most promising drug candidates in development for the potential treatment of neuropathic pain?* Which neuropathic pain subtypes represent the most lucrative indications in which to seek regulatory approval? [Studien Infos ausblenden] |
|||||||||||
|
Executive Summary Strategic scoping and focus Datamonitor insight into the neuropathic pain market Related reports OVERVIEW Catalyst Summary 1. PATIENT POTENTIAL Key findings Definition of neuropathic pain Neuropathic pain can be defined by location, etiology, and severity Diagnosis of neuropathic pain Patient segmentation Segmentation of neuropathic pain largely depends on the subtype Segmentation of neuropathic pain differs depending on the symptoms Epidemiology of neuropathic pain in the seven major markets Neuropathic low back pain is the most prevalent of the neuropathic pain indications, affecting an estimated 29 million individuals across the seven major markets Diabetic neuropathic pain affects an estimated 683,000 patients across the seven major markets HIV-related neuropathic pain affects an estimated 332,000 people in the seven major markets Post-herpetic neuralgia affects an estimated 307,000 people across the seven major markets Other neuropathic pain subtypes Current management of neuropathic pain Treatments of neuropathic pain can involve pharmacological and non-pharmacological approaches Consequences of inadequately treated neuropathic pain Unmet need in neuropathic pain The primary unmet need is improved efficacy in pain reduction and management After efficacy, improved side-effect profile is the second most important unmet need Reduction in pill burden will be increasingly important in the future with the use of combination therapies Fewer drug-drug interactions will strengthen pipeline agents profile for use as a conjunctive therapy Reduced time to onset of action is the least important unmet need 2. MARKET OVERVIEW Market definition for this report Seven major markets Key events impacting the neuropathic pain market Current and future market overview US Current and future market assessment Japan Current and future market assessment Five major European markets Current and future market assessment France Germany Italy Spain UK 3. BRAND DYNAMICS Overview of competitive landscape Six treatments are currently marketed for neuropathic pain Off-label prescribing US formulary tier status for leading brands Lyrica (pregabalin; Pfizer) Drug overview Drug profile Product positioning SWOT analysis Brand forecast to 2019 Cymbalta (duloxetine; Eli Lilly/Shionogi) Drug overview Drug profile Product positioning SWOT analysis Brand forecast to 2019 Lidoderm (5% lidocaine patch; Endo/Grünenthal/Teikoku) Drug overview Drug profile Product positioning SWOT analysis Brand forecast to 2019 Qutenza (8% capsaicin patch; NeurogesX/Astellas) Brand overview Brand profile Product positioning SWOT analysis Brand forecast to 2019 Other brands indicated for neuropathic pain Neurontin (gabapentin; Pfizer) Tegretol XR/CR (extended-release carbamazepine; Novartis) 4. PIPELINE OVERVIEW AND R&D DYNAMICS Pipeline overview Clinical pipeline Classification of pipeline products Glutamate receptor modulators Ion channel modulators GABA modulators Others Comparative forecasts Datamonitor pipeline assessment summary Definition of current comparator therapy Pfizer’s Lyrica is Datamonitor’s comparator therapy for non-topical neuropathic pain treatments Endo’s Lidoderm is the topical comparator therapy Pipeline candidates need to address efficacy, dosing regime, and side effects 5. R&D APPROACH R&D approach differs depending on the geographic market General neuropathic pain provides a broader customer base in the EU and Japan US approval requires evidence in each neuropathic pain subtype Clinical trial design in neuropathic pain Choice of endpoint is the key clinical trial design factor in neuropathic pain Clinical trial endpoints in neuropathic pain A key challenge inherent in neuropathic pain clinical trials is recruitment of a homogenous, treatment-naïve patient population 6. PIPELINE ANALYSIS AND FORECASTS: GLUTAMATE MODULATORS Pipeline summary NP-1 (amitriptyline and ketamine; EpiCept) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor’s drug assessment score card for NP-1 Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 AVP-923 (dextromethorphan hydrobromide and quinidine sulfate; IriSys/Avanir) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for AVP-923 Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Forecasts to 2019 Other glutamate modulators NT11624 (dimiracetam; Brane Discovery/Neurotune) 7. PIPELINE ANALYSIS AND FORECASTS: ION CHANNEL MODULATORS Pipeline summary Ralfinamide (NW-1029; Newron) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for ralfinamide Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 Eladur (bupivacaine patch; Durect/King/Pfizer) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for Eladur Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 Other ion channel modulators BIA 2-093 (eslicarbazepine acetate; Bial) 2PX (strontium chloride; SantoSolve AS) 8. PIPELINE ANALYSIS AND FORECASTS: GABA MODULATORS Pipeline summary DM-1796 (extended-release gabapentin; Depomed/Abbott) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for DM-1796 Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 Horizant (gabapentin enacarbil; XenoPort/GlaxoSmithKline/Astellas) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for Horizant Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 9. PIPELINE ANALYSIS AND FORECASTS: OTHER Pipeline summary Nucynta ER (extended-release tapentadol HCl; Johnson & Johnson/Grünenthal) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for Nucynta ER Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 ARC-4558 (clonidine HCl; Arcion) Drug overview Drug profile Development overview Clinical trial data SWOT analysis Datamonitor drug assessment score card for ARC-4558 Clinical attractiveness Commercial attractiveness Satisfaction of unmet needs Brand forecast to 2019 Other pipeline candidates Sativex (tetrahydrocannabinol and cannabidiol; GW Pharma/Bayer) ADL5859/PF4856880 (Adolor) BIBLIOGRAPHY Patient potential Journals Publications and online articles Market overview Publications and online articles Brand dynamics Journals Publications and online articles Pipeline overview and R&D dynamics Journals Publications and online articles R&D approach Journals Pipeline analysis and forecasts: glutamate modulators Publications and online articles Pipeline analysis and forecasts: ion channel modulators Journals Publications and online articles Pipeline analysis and forecasts: GABA modulators Publications and online articles Pipeline analysis and forecasts: other Journals Publications and online articles Datamonitor reports APPENDIX Forecast assumptions New product launches Generic launches Methodology Datamonitor forecast methodology Product forecasts Definition of a standard unit Derivation of sales forecasts and pricing trends Exchange rates Datamonitor drug assessment scorecard Contributing experts [Inhaltsverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
